Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Africa

- PMLiVE

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

Lilly revealed expanded findings from phase 2 TRAILBLAZER-ALZ study this week

- PMLiVE

EMA starts rolling review of Lilly’s COVID-19 antibodies

CHMP will review the combination of bamlanivimab and etesemivab as well as bamlanivimab monotherapy

- PMLiVE

Lilly partners with Biolojic Design to develop diabetes antibody therapies

Agreement could be worth up to $121m in milestone payments

- PMLiVE

EMA recommends use of Lilly’s COVID-19 antibody cocktail

Agency concludes bamlanivimab and etesevimab can be used to treat certain COVID-19 patients

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Companies will co-develop molecules for the treatment of immunological and neurodegenerative diseases

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

FDA grants emergency use for Lilly’s COVID-19 antibody drug combination

Bamlanivimab plus etesevimab shown to reduce risk of death in high-risk COVID-19 patients

- PMLiVE

Eli Lilly promotes Anat Ashkenazi to chief financial officer

Ashkenazi previously served as CFO of Lilly Research Laboratories

- PMLiVE

Lilly partners with GSK and Vir on COVID-19 antibody study

Study will test Lilly's bamlanivimab with GSK/Vir’s VIR-7831

- PMLiVE

Eli Lilly’s COVID-19 antibody combination reduces risk of hospitalisations and death

High-risk patients treated with the two drugs had a 70% reduction in hospitalisation and death

- PMLiVE

Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%

Bamlanivimab-treated care home residents and staff had a significant reduction in COVID-19 risk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links